Early trial shows investigational orexin-2 agonist ALKS 7290 improves adult ADHD symptoms in 14 days, with tolerable safety, paving way for phase 2.
|Slideshows|March 23, 2018
3 Clinical Studies on ADHD
Author(s)Mark L. Fuerst
Highlights of 3 studies find that novel genetic variants for ADHD are linked to educational attainment; the prevalence of parent-reported ADHD diagnoses has not increased recently; and a video game-like intervention targets cognitive processes implicated in ADHD.
Advertisement
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Psychiatric Times
1
Olanzapine LAI (Weltruza) Receives FDA Approval for Schizophrenia
2
FDA Grants Clearance to Motivista, the First Authorized Treatment for Negative Symptoms of Schizophrenia
3
Moving Away From Treatment-Resistant Depression and Toward Difficult-to-Treat Depression
4
Vortioxetine's Effect on Cognitive Function in Older Adults With Major Depressive Disorder
5